Sunday, November 7, 2021
- 8:30AM-10:30AM
-
Abstract Number: 0661
Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)- 8:30AM-10:30AM
-
Abstract Number: 0921
Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0930
Effect of Tofacitinib on Spinal Vertebral Body and Posterolateral Element Inflammation and Structural Lesions Using the Canada-Denmark MRI Scoring System in Patients with Ankylosing Spondylitis: Results from a Phase 2 Study
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0599
Effectiveness of a Provider Led Intervention on Medication Adherence in an Urban Lupus Clinic
Healthcare Disparities in Rheumatology Poster (0594–0622)- 8:30AM-10:30AM
-
Abstract Number: 0588
Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Patients with Rheumatoid Arthritis: Data from the ACR’s RISE Registry
Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)- 8:30AM-10:30AM
-
Abstract Number: 0833
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)- 8:30AM-10:30AM
-
Abstract Number: 0560
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)- 8:30AM-10:30AM
-
Abstract Number: 0935
Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0912
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients with Early versus Late Disease Through Week 52 of GO-ALIVE Study
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0924
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0917
Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA
Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)- 8:30AM-10:30AM
-
Abstract Number: 0725
Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia
Osteoarthritis – Clinical Poster II (0723–0738)- 8:30AM-10:30AM
-
Abstract Number: 0737
Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
Osteoarthritis – Clinical Poster II (0723–0738)